Medicina Fluminensis, Vol. 61 No. 1, 2025.
Pregledni rad
https://doi.org/10.21860/medflum2025_323583
The Role of Infusion Therapy in The Treatment of Advanced Parkinson’s Disease
Mario Hero
; Klinički bolnički centar Rijeka, Klinika za neurologiju, Rijeka, Hrvatska
*
Valentino Rački
; Klinički bolnički centar Rijeka, Klinika za neurologiju, Rijeka, Hrvatska
Vladimira Vuletić
; Klinički bolnički centar Rijeka, Klinika za neurologiju, Rijeka, Hrvatska
Olivio Perković
; Klinički bolnički centar Rijeka, Klinika za neurologiju, Rijeka, Hrvatska
* Dopisni autor.
Sažetak
Parkinson’s disease (PD) is the second most common neurodegenerative disease, marked by motor and non-motor symptoms due to dopaminergic neuron loss. In the past three decades, PD prevalence has significantly increased, arousing growing interest in exploring advanced treatment methods, especially for advanced stages of the disease. The advanced stage of PD is characterized by an inadequate response to oral therapy as well as motor fluctuations and dyskinesias. In response to these challenges, invasive therapeutic options such as infusion therapies have been developed, representing a significant advance in treating advanced PD. This review covers currently available infusion therapies used in PD patients. The first infusion therapy used in PD was the apomorphine subcutaneous pump, which has been used for 30 years and effectively reduces motor fluctuations and dyskinesias. Levodopa/carbidopa intestinal gel also reduces “OFF” periods and improves patients’ quality of life, with effectiveness in addressing non-motor symptoms as well. Levodopa/carbidopa/entacapone intestinal gel therapy allows for a similar therapeutic effect with a lower drug dose due to the addition of entacapone. The foslevodopa/foscarbidopa subcutaneous pump is a newer therapeutic option that achieves the same therapeutic effects without the need for an invasive procedure. Its advantage over enteral pumps is that it does not require an invasive procedure, such as the placement of a tube in the digestive tract. Selecting patients for these therapies requires a detailed assessment of symptoms and response to treatment. Although these treatment methods do not affect the underlying neurodegenerative process, they are crucial in symptom management.
Ključne riječi
carbidopa; drug combination; drug therapy; home infusion therapy; levodopa; Parkinson disease
Hrčak ID:
323583
URI
Datum izdavanja:
1.3.2025.
Posjeta: 240 *